Maine individual market rate filing
We recently submitted a rate filing to the Maine Bureau of Insurance for regulatory review. If the Maine Bureau of Insurance approves our request, this change will apply to your premium beginning January 2027.
Get the latest word on plan news, benefit changes, Harvard Pilgrim developments and federal health care reform updates
We recently submitted a rate filing to the Maine Bureau of Insurance for regulatory review. If the Maine Bureau of Insurance approves our request, this change will apply to your premium beginning January 2027.
The parent company of Harvard Pilgrim Health Care and Tufts Health Plan, Point32Health, was named to Points of Light’s The Civic 50® for the sixth time.
Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, today announced a comprehensive digital transformation initiative in partnership with League and Availity to deliver a more modern, unified and simpler experience for both members and providers.
Point32Health today reported an adjusted net loss of $141 million for the 12 months ended Dec. 31, 2025.
Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, today announced the appointment of Jeff Weiss as executive vice president, corporate strategy and strategic partnerships, and Marti Lolli as executive vice president, chief growth officer.
Maine law requires health plans to honor referrals from out-of-network Direct Health Care (DHC) providers.
A total of 34 physician groups in the Harvard Pilgrim commercial provider network have been named to Harvard Pilgrim Health Care’s 24th annual Physician Group Honor Roll.
Harvard Pilgrim Health Care, a Point32Health company, and Northern Light Health are working together to bring affordable, high-quality health care coverage for those living in Maine.
Conduent, a vendor that audits medical bills sent to Harvard Pilgrim Health Care and Tufts Health Plan, was the victim of a cyber incident.
Most 2026 plans will exclude pharmacy coverage for weight loss medications, including GLP-1s approved for conditions other than diabetes.